Mira Pharmaceuticals Inc
Research Mira Pharmaceuticals Inc (MIRA) on Bullrun: market cap USD 32.57M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMIRA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Market capUSD 32.57M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 1.15M
- Free cash flow-USD 1.20M
Valuation Snapshot
latest market cap is USD 32.57M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 10.44M | -USD 4.66M | n/a | -1.35 | USD 6.35M | n/a | USD 10.39M |
| FY2024 | USD 0 | -USD 7.85M | -USD 5.56M | n/a | -0.51 | USD 2.83M | USD 0 | USD 2.20M |
| FY2023 | USD 0 | -USD 11.98M | -USD 4.53M | n/a | -0.85 | USD 4.60M | USD 5.06K | USD 4.37M |
| FY2022 | n/a | -USD 7.06M | n/a | n/a | -0.4 | USD 350.98K | n/a | -USD 596.23K |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 32.57M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 63.33M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 18.88M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 15.52M | n/a | n/a | n/a |
About Mira Pharmaceuticals Inc
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Mira Pharmaceuticals Inc's market cap?
Mira Pharmaceuticals Inc's market capitalization is USD 32.57M.
What does Mira Pharmaceuticals Inc do?
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial.